Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BJ045
- Development stage
- Preclinical
- Lead developer
- Shanghai Bao Pharmaceuticals
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
BJ045 is an investigational recombinant protein therapeutic being developed by Shanghai Bao Pharmaceuticals for the treatment of IgG-mediated autoimmune diseases. Currently in the preclinical stage of development, BJ045 is designed to rapidly deplete circulating Immunoglobulin G (IgG) antibodies, which are the primary drivers of pathology in various autoimmune conditions. It is positioned within the developer's pipeline alongside Ricefidase (KJ103), a recombinant IgG-degrading enzyme (IdeS), suggesting that BJ045 may utilize a similar enzymatic mechanism to cleave or degrade pathogenic autoantibodies to alleviate disease symptoms.
02
Targets
Beyond the preview
Go deeper on BJ045.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BJ045.